News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) Hopes to End Novo Nordisk A/S (NVO)'s Stranglehold on the GLP-1 Market


6/27/2013 10:30:28 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Competition in the GLP-1 market is heating up. Byetta (Exenatide) was first to the market but was quickly overtaken once Novo Nordisk (NVO) released Victoza (Liraglutide). Victoza now makes up 13% of Novo Nordisk's revenue and with 35% growth last quarter it leads all their other medications in growth prospects. Eli Lilly (LLY) has grand ambitions to expand their product line in the diabetes market which is Novo Nordisk's bread and butter. Their first salvo looks to be a GLP-1 agonist called Dulaglutide. Currently Victoza (Liraglutide) controls 68%of the GLP-1 market. With GLP-1 drugs steadily increasing in use it will end up being a much larger market.

Help employers find you! Check out all the jobs and post your resume.

Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES